$MRNA
Moderna, Inc.

2021 Q4 Form 10-Q Financial Statement

#000168285221000027 Filed on November 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $7.211B $4.969B $157.0M
YoY Change 1163.54% 3064.97% 821.04%
Cost Of Revenue $952.0M $722.0M $0.00
YoY Change 11950.63%
Gross Profit $6.259B $4.247B $157.0M
YoY Change 1012.12% 2605.1%
Gross Profit Margin 86.8% 85.47% 100.0%
Selling, General & Admin $201.0M $168.0M $48.50M
YoY Change 154.43% 246.39% 71.99%
% of Gross Profit 3.21% 3.96% 30.89%
Research & Development $648.0M $521.0M $344.0M
YoY Change -14.61% 51.45% 187.54%
% of Gross Profit 10.35% 12.27% 219.11%
Depreciation & Amortization $78.00M $70.00M $8.000M
YoY Change 900.0% 775.0% 9.59%
% of Gross Profit 1.25% 1.65% 5.1%
Operating Expenses $849.0M $521.0M $393.0M
YoY Change 1.32% 32.56% 165.9%
Operating Profit $5.410B $3.558B -$235.0M
YoY Change -2066.56% -1614.04% 79.71%
Interest Expense $0.00 $0.00 $2.900M
YoY Change -100.0% -100.0% -62.34%
% of Operating Profit 0.0% 0.0%
Other Income/Expense, Net $0.00 -$10.00M -$3.000M
YoY Change -100.0% 233.33% 59.49%
Pretax Income $5.410B $3.552B -$232.0M
YoY Change -2096.31% -1631.03% 88.02%
Income Tax $542.0M $219.0M $1.000M
% Of Pretax Income 10.02% 6.17%
Net Earnings $4.868B $3.333B -$233.0M
YoY Change -1886.42% -1530.47% 89.1%
Net Earnings / Revenue 67.51% 67.08% -148.41%
Basic Earnings Per Share $8.27 -$0.59
Diluted Earnings Per Share $11.29M $7.70 -$0.59
COMMON SHARES
Basic Shares Outstanding 405.4M shares 404.0M shares 395.0M shares
Diluted Shares Outstanding 434.0M shares 395.0M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.73B $8.906B $3.277B
YoY Change 132.79% 171.8% 209.55%
Cash & Equivalents $6.848B $5.550B $1.506B
Short-Term Investments $3.879B $3.356B $1.771B
Other Short-Term Assets $28.00M $43.00M $87.00M
YoY Change 154.55% -50.57% 690.91%
Inventory $1.441B $965.0M
Prepaid Expenses
Receivables $3.175B $3.142B $190.5M
Other Receivables $121.0M $57.00M $22.00M
Total Short-Term Assets $16.07B $13.43B $3.577B
YoY Change 155.18% 275.29% 226.85%
LONG-TERM ASSETS
Property, Plant & Equipment $1.383B $960.0M $369.0M
YoY Change 257.36% 160.16% 81.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $6.843B $6.442B $692.0M
YoY Change 970.89% 830.92% 147.14%
Other Assets $34.00M $4.000M $2.047M
YoY Change 1600.0% 95.41% -2.24%
Total Long-Term Assets $8.598B $7.498B $1.074B
YoY Change 727.53% 598.36% 116.28%
TOTAL ASSETS
Total Short-Term Assets $16.07B $13.43B $3.577B
Total Long-Term Assets $8.598B $7.498B $1.074B
Total Assets $24.67B $20.92B $4.651B
YoY Change 236.23% 349.87% 192.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $302.0M $87.00M $20.52M
YoY Change 1577.78% 323.96% 74.84%
Accrued Expenses $1.472B $1.076B $208.8M
YoY Change 213.19% 415.25% 247.6%
Deferred Revenue $6.253B $7.977B $1.235B
YoY Change 61.7% 546.17% 1658.78%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $165.0M $218.0M
YoY Change 587.5%
Total Short-Term Liabilities $9.128B $9.957B $1.474B
YoY Change 107.97% 575.71% 896.71%
LONG-TERM LIABILITIES
Long-Term Debt $599.0M $238.0M $109.0M
YoY Change 444.55% 118.35% 220.59%
Other Long-Term Liabilities $76.00M $1.000M $2.183M
YoY Change 2433.33% -54.19% 1255.9%
Total Long-Term Liabilities $76.00M $1.000M $2.183M
YoY Change 2433.33% -54.19% 1255.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.128B $9.957B $1.474B
Total Long-Term Liabilities $76.00M $1.000M $2.183M
Total Liabilities $10.52B $10.80B $1.891B
YoY Change 120.35% 471.05% 457.69%
SHAREHOLDERS EQUITY
Retained Earnings $9.958B $5.090B -$1.970B
YoY Change -543.76% -358.38% 43.84%
Common Stock $0.00 $0.00 $40.00K
YoY Change -100.0% 21.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.15B $10.12B $2.760B
YoY Change
Total Liabilities & Shareholders Equity $24.67B $20.92B $4.651B
YoY Change 236.23% 349.87% 192.34%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $4.868B $3.333B -$233.0M
YoY Change -1886.42% -1530.47% 89.1%
Depreciation, Depletion And Amortization $78.00M $70.00M $8.000M
YoY Change 900.0% 775.0% 9.59%
Cash From Operating Activities $3.310B $3.276B $892.8M
YoY Change 161.8% 266.94% -934.39%
INVESTING ACTIVITIES
Capital Expenditures -$120.0M -$99.00M -$19.20M
YoY Change 415.02% 415.63% 186.57%
Acquisitions
YoY Change
Other Investing Activities -$1.018B -$3.228B -$1.159B
YoY Change 510.31% 178.52% -1065.03%
Cash From Investing Activities -$1.138B -$3.327B -$1.178B
YoY Change 498.63% 182.36% -1139.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -873.0M -2.000M 29.70M
YoY Change -2079.59% -106.73% 87.97%
NET CHANGE
Cash From Operating Activities 3.310B 3.276B 892.8M
Cash From Investing Activities -1.138B -3.327B -1.178B
Cash From Financing Activities -873.0M -2.000M 29.70M
Net Change In Cash 1.299B -53.00M -255.8M
YoY Change 16.16% -79.28% -1252.25%
FREE CASH FLOW
Cash From Operating Activities $3.310B $3.276B $892.8M
Capital Expenditures -$120.0M -$99.00M -$19.20M
Free Cash Flow $3.430B $3.375B $912.0M
YoY Change 166.39% 270.07% -1009.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
Moderna, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001682852
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q3 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38753
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3467528
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2624000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
3356000000 USD
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Technology Square
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge,
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
714-6500
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
MRNA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
405449527 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5550000000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
34000000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1984000000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3142000000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1391000000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
965000000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
47000000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
412000000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
252000000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
13425000000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
6298000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
6442000000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
639000000 USD
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
845000000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
297000000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
115000000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
90000000 USD
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11000000 USD
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11000000 USD
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
81000000 USD
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4000000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2000000 USD
CY2021Q3 us-gaap Assets
Assets
20923000000 USD
CY2020Q4 us-gaap Assets
Assets
7337000000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
87000000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18000000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1076000000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
470000000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7977000000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3867000000 USD
CY2021Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
565000000 USD
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
0 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
252000000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9957000000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4389000000 USD
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
498000000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
177000000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105000000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
97000000 USD
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
238000000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
110000000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1000000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3000000 USD
CY2021Q3 us-gaap Liabilities
Liabilities
10799000000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
4776000000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
162000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1600000000 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
405000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
405000000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
399000000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
399000000 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
0 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5003000000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4802000000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
31000000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
5090000000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2244000000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
10124000000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2561000000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20923000000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7337000000 USD
CY2021Q3 us-gaap Revenues
Revenues
4969000000 USD
CY2020Q3 us-gaap Revenues
Revenues
157000000 USD
us-gaap Revenues
Revenues
11260000000 USD
us-gaap Revenues
Revenues
232000000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
722000000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1665000000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
521000000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
344000000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1343000000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
611000000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
168000000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48000000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
366000000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
109000000 USD
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
1411000000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
392000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
3374000000 USD
us-gaap Costs And Expenses
CostsAndExpenses
720000000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3558000000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-235000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
7886000000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-488000000 USD
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000000 USD
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
6000000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
11000000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
21000000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22000000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3552000000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-232000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7875000000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-473000000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
219000000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
541000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
3333000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-233000000 USD
us-gaap Net Income Loss
NetIncomeLoss
7334000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-474000000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.27
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
18.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.26
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.70
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
17.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.26
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
404000000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
395000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
402000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376000000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
434000000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
395000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
431000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376000000 shares
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
3333000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-233000000 USD
us-gaap Net Income Loss
NetIncomeLoss
7334000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-474000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
1000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
2000000 USD
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
-1000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-4000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-3000000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-12000000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
30000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
0 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
51000000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
0 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
11000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
0 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
11000000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
0 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
19000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
0 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
40000000 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent
OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
0 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
28000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3000000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3348000000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-236000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7362000000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-471000000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
6704000000 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15000000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
3333000000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
10124000000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
2947000000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22000000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-233000000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2760000000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
2561000000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
91000000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
105000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
28000000 USD
us-gaap Net Income Loss
NetIncomeLoss
7334000000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
10124000000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1175000000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2000000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1853000000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
133000000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3000000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
67000000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
3000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-474000000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
2760000000 USD
us-gaap Net Income Loss
NetIncomeLoss
7334000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-474000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
105000000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
67000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
154000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24000000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-33000000 USD
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-5000000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-89000000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1751000000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
185000000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
186000000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
68000000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
918000000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
25000000 USD
mrna Increase Decrease In Right Of Use Asset Operating Leases
IncreaseDecreaseInRightOfUseAssetOperatingLeases
13000000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
26000000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
14000000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
600000000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
132000000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4431000000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1240000000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
565000000 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0 USD
mrna Operating Lease Liabilities
OperatingLeaseLiabilities
8000000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
1075000000 USD
mrna Operating Lease Liabilities
OperatingLeaseLiabilities
14000000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
23000000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
7000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10310000000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
763000000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
10279000000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
2326000000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
748000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1983000000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
140000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
164000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
44000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7385000000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1482000000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1853000000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
96000000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
136000000 USD
mrna Charges To Financing Lease Liabilities
ChargesToFinancingLeaseLiabilities
-96000000 USD
mrna Charges To Financing Lease Liabilities
ChargesToFinancingLeaseLiabilities
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1989000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2925000000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1270000000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2636000000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
248000000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5561000000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1518000000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
66000000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
13000000 USD
mrna Right Of Use Assets Obtained Through Finance Lease Modifications And Reassessments
RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments
364000000 USD
mrna Right Of Use Assets Obtained Through Finance Lease Modifications And Reassessments
RightOfUseAssetsObtainedThroughFinanceLeaseModificationsAndReassessments
46000000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
126000000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 USD
mrna Number Of Development Program
NumberOfDevelopmentProgram
37 program
mrna Number Of Development Programs That Have Entered Clinics Number Of Clinics
NumberOfDevelopmentProgramsThatHaveEnteredClinicsNumberOfClinics
22 program
us-gaap Use Of Estimates
UseOfEstimates
We have made estimates and judgments affecting the amounts reported in our condensed consolidated financial statements and the accompanying notes. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods that are not readily apparent from other sources. Significant estimates relied upon in preparing these financial statements include, but are not limited to, critical accounting policies or estimates related to revenue recognition, research and development expenses, stock-based compensation, leases, fair value of financial instruments, derivative financial instruments, inventory, useful lives of property and equipment, income taxes and our valuation allowance on our deferred tax assets. The actual results that we experience may differ materially from our estimates.
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2000000 USD
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15000000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5550000000 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1506000000 USD
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 USD
CY2020Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1000000 USD
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11000000 USD
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
11000000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5561000000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1518000000 USD
mrna Number Of Participant
NumberOfParticipant
30000 option
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
3356000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
3356000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
6450000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
6442000000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9806000000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
9798000000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
1981000000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
1984000000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
638000000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
639000000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
2619000000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
2623000000 USD
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 USD
CY2020Q3 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 USD
CY2021Q3 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 USD
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0 USD
CY2020Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
CY2021Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 USD
us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
51000000 USD
CY2021Q3 us-gaap Foreign Currency Cash Flow Hedge Gain Loss To Be Reclassified During Next12 Months
ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
48000000 USD
CY2021Q3 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1992000000 USD
CY2021Q3 us-gaap Derivative Assets
DerivativeAssets
51000000 USD
CY2021Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
1000000 USD
CY2021Q3 us-gaap Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax
OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
30000000 USD
CY2021Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
605000000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
37000000 USD
CY2021Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
233000000 USD
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
845000000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
297000000 USD
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
70000000 USD
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
154000000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
9000000 USD
CY2021Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
127000000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1000000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
965000000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
47000000 USD
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
1119000000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
417000000 USD
CY2021Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
274000000 USD
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
120000000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24000000 USD
CY2021Q3 mrna Other Prepaid Expense Manufacturing
OtherPrepaidExpenseManufacturing
156000000 USD
CY2020Q4 mrna Other Prepaid Expense Manufacturing
OtherPrepaidExpenseManufacturing
217000000 USD
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
105000000 USD
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
7000000 USD
CY2021Q3 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
57000000 USD
CY2020Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
7000000 USD
CY2021Q3 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
51000000 USD
CY2020Q4 us-gaap Derivative Assets Current
DerivativeAssetsCurrent
0 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
43000000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
21000000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
412000000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
252000000 USD
CY2021Q3 mrna Accrued Clinical Trials
AccruedClinicalTrials
166000000 USD
CY2020Q4 mrna Accrued Clinical Trials
AccruedClinicalTrials
98000000 USD
CY2021Q3 mrna Raw Materials Accounts Payable
RawMaterialsAccountsPayable
141000000 USD
CY2020Q4 mrna Raw Materials Accounts Payable
RawMaterialsAccountsPayable
78000000 USD
CY2021Q3 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
168000000 USD
CY2020Q4 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
0 USD
CY2021Q3 mrna Accrued Development Operation
AccruedDevelopmentOperation
125000000 USD
CY2020Q4 mrna Accrued Development Operation
AccruedDevelopmentOperation
29000000 USD
CY2021Q3 mrna Accrued Manufacturing
AccruedManufacturing
196000000 USD
CY2020Q4 mrna Accrued Manufacturing
AccruedManufacturing
53000000 USD
CY2021Q3 mrna Accrued Other External Goods And Services Current
AccruedOtherExternalGoodsAndServicesCurrent
87000000 USD
CY2020Q4 mrna Accrued Other External Goods And Services Current
AccruedOtherExternalGoodsAndServicesCurrent
92000000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
105000000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
95000000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
88000000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
25000000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1076000000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
470000000 USD
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
218000000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
24000000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
22000000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6000000 USD
CY2021Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
12000000 USD
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
4000000 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
252000000 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
252000000 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
34000000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4044000000 USD
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
9658000000 USD
mrna Contract With Customer Liability Deductions During Period
ContractWithCustomerLiabilityDeductionsDuringPeriod
5227000000 USD
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
8475000000 USD
CY2021Q3 mrna Operating Lease Number Of Properties
OperatingLeaseNumberOfProperties
2 numberOfCampuses
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
115000000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
90000000 USD
CY2021Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
416000000 USD
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
55000000 USD
CY2021Q3 mrna Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
531000000 USD
CY2020Q4 mrna Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
145000000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
22000000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6000000 USD
CY2021Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
218000000 USD
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
24000000 USD
CY2021Q3 mrna Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
240000000 USD
CY2020Q4 mrna Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
30000000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105000000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
97000000 USD
CY2021Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
238000000 USD
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
110000000 USD
CY2021Q3 mrna Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
343000000 USD
CY2020Q4 mrna Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
207000000 USD
CY2021Q3 mrna Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
583000000 USD
CY2020Q4 mrna Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
237000000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7000000 USD
CY2021Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
66000000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
31000000 USD
CY2021Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
173000000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
25000000 USD
CY2021Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
19000000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
16000000 USD
CY2021Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
19000000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
17000000 USD
CY2021Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
19000000 USD
CY2021Q3 mrna Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
94000000 USD
CY2021Q3 mrna Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
600000000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
190000000 USD
CY2021Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
896000000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
63000000 USD
CY2021Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
440000000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
127000000 USD
CY2021Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
456000000 USD
CY2017Q2 mrna Research And Development Arrangement Contract To Perform For Others Commercial Milestones Maximum Amount
ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount
24000000 USD
CY2021Q3 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
168000000 USD
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
400000000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
58000000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
34060000.00 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.14
CY2020Q4 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
9.12
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2976000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1280000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
195.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
86.02
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5690000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
15.77
mrna Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
8.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
860000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
26.97
mrna Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue
14.51
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
28790000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.09
CY2021Q3 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
12.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10362000000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
16840000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.68
CY2021Q3 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
6.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6266000000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11950000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
42.56
CY2021Q3 mrna Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue
20.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M6D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4096000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1200000000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
91000000 USD
us-gaap Restricted Stock Expense
RestrictedStockExpense
13000000 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40000000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22000000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
105000000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67000000 USD
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40000000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22000000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
105000000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
67000000 USD
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
348000000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2021Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
1000000000 USD
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
0 USD
CY2021Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
0 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
219000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
541000000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000000 USD
CY2021Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.06
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.07
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-49000000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
3333000000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-233000000 USD
us-gaap Net Income Loss
NetIncomeLoss
7334000000 USD
us-gaap Net Income Loss
NetIncomeLoss
-474000000 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
404000000 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
395000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
402000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376000000 shares
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
30000000 shares
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
30000000 shares
CY2020Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
29000000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
434000000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
395000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
431000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376000000 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.27
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
18.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.26
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.70
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
17.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.26
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39000000 shares

Files In Submission

Name View Source Status
0001682852-21-000027-index-headers.html Edgar Link pending
0001682852-21-000027-index.html Edgar Link pending
0001682852-21-000027.txt Edgar Link pending
0001682852-21-000027-xbrl.zip Edgar Link pending
a4exhibit3119302021.htm Edgar Link pending
a5exhibit3129302021.htm Edgar Link pending
a6exhibit3219302021.htm Edgar Link pending
exhibit101amendmentsnos12t.htm Edgar Link pending
exhibit102amendmentno10bar.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_19a.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
mrna-20210930.htm Edgar Link pending
mrna-20210930.xsd Edgar Link pending
mrna-20210930_cal.xml Edgar Link unprocessable
mrna-20210930_def.xml Edgar Link unprocessable
mrna-20210930_g1.jpg Edgar Link pending
mrna-20210930_g2.jpg Edgar Link pending
mrna-20210930_g3.jpg Edgar Link pending
mrna-20210930_htm.xml Edgar Link completed
mrna-20210930_lab.xml Edgar Link unprocessable
mrna-20210930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending